Stage 1: History & Presentation (Timestamp: 6 Months Prior to Admission)
A 54-year-old female schoolteacher (residing in Delhi NCR, no prior autoimmune history or tobacco use) presents to the emergency department with a 6-month history of subacute progressive exertional breathlessness, dry cough, polyarthralgias, and constitutional symptoms.
HPI:
- 6 Months Ago: Developed symmetrical joint pain and morning stiffness (>1 hour) involving her wrists, metacarpophalangeal (MCP) joints, and proximal interphalangeal (PIP) joints, accompanied by cold-induced digital pallor and cyanosis (Raynaud's phenomenon).
- 3 Months Ago: Developed insidious exertional dyspnea (NYHA Class II to III), dry cough, low-grade fevers (38.0°C), unintentional 6 kg weight loss, and rough, fissured, hyperkeratotic skin changes along the radial margins of her index fingers and thumbs ("mechanic's hands").
- Presenting Event: Worsening orthopnea and chest pressure prompting emergency department evaluation.
- Medical & Social History: HTN on Amlodipine. Non-smoker, no history of occupational dust exposures or illicit drug use.
Hello, Chief Resident here.
Key Findings: A 54-year-old female presenting with progressive ILD features (exertional dyspnea, dry cough, orthopnea), symmetric inflammatory polyarthritis (wrists/MCPs/PIPs), Raynaud's phenomenon, weight loss, fevers, and pathognomonic "mechanic's hands."
Differential Diagnoses:
1. Anti-Synthetase Syndrome (ASS) (65%): Highest probability; features the classic pentad/triad of ILD, mechanic's hands, inflammatory arthritis, Raynaud's, and constitutional symptoms.
2. Systemic Sclerosis (SSc) ILD (20%): Considered due to Raynaud's, subacute ILD, and joint involvement, though mechanic's hands specifically point toward ASS.
3. Rheumatoid Arthritis-associated ILD (RA-ILD) (10%): Supported by symmetrical small-joint polyarthritis with >1 hour morning stiffness and respiratory symptoms.
4. Mixed Connective Tissue Disease (MCTD) (5%): Suggested by overlapping features of Raynaud's, arthritis, and lung involvement.
Recommended Prioritized Tests:
1. Myositis-Specific/Associated Autoantibody Panel (including Anti-Jo-1, Anti-PL-7, Anti-PL-12, Anti-EJ).
2. High-Resolution CT (HRCT) Chest to assess ILD pattern (e.g., NSIP, OP, or UIP).
3. Serum Muscle Enzymes (CPK, Aldolase, LDH, AST/ALT) to evaluate subclinical myositis.
4. Autoimmune Serologies (ANA, Anti-CCP, RF, Anti-Scl-70, Anti-U1-RNP).
5. Pulmonary Function Tests (PFTs) with DLCO to baseline lung volumes and gas exchange.
Hello Attending Consultant here
Top 3 DDx:
1. Anti-synthetase syndrome (Jo-1 or non-Jo-1)
2. MDA5+ dermatomyositis (amyopathic ILD phenotype)
3. SSc-sine-scleroderma / overlap CTD-ILD
Critique of plan: Solid prioritization of ASS; probabilities slightly overweighted toward classic Jo-1. Mechanic’s hands + RP + arthritis + subacute ILD is highly specific, but early MDA5 or PL-7/PL-12 variants can present identically without frank myositis. RA-ILD less likely absent erosions/high-titer CCP. MCTD improbable without anti-U1-RNP dominance.
5 specific refinements:
1. Add anti-MDA5, anti-Ro52, and extended ARS panel (OJ, KS, Zo, Ha) immediately—non-Jo-1 carry worse ILD prognosis.
2. Urgent HRCT + PFTs/DLCO; quantify GGO vs consolidation for OP/NSIP vs rapidly progressive phenotype.
3. Baseline echo + NT-proBNP to exclude PAH/myocarditis before immunosuppression.
4. Nailfold capillaroscopy now—distinguishes SSc-spectrum.
5. Hold empiric steroids until serologies/HRCT; consider early IVIG/ritux if MDA5+ or hypoxemic.
6. Screen for occult malignancy (age/sex-appropriate) given constitutional features.
7. Multidisciplinary ILD-rheum board within 48 h.
Hello, Expert Clinician here.
Best unifying diagnosis: Anti-synthetase syndrome (ASS) with ILD — the tetrad of inflammatory arthritis, Raynaud's, mechanic's hands, and subacute ILD is near-pathognomonic. Suspect non–Jo-1 ARS (PL-7/PL-12), which skews toward ILD-dominant, myositis-poor presentations.
Top differentials:
- MDA5+ clinically amyopathic dermatomyositis: fits mechanic's hands and rapidly progressive ILD; less likely without ulceration/ Gottron's, but must be excluded — it dictates urgency.
- SSc/overlap CTD-ILD: Raynaud's + ILD fit; mechanic's hands and prominent arthritis argue against.
- RA-ILD: arthritis fits, but Raynaud's + mechanic's hands are unexplained.
- IPAF: diagnosis of exclusion only.
Key pivot: Mechanic's hands — it converts "arthritis + ILD" from RA-ILD into a myositis-spectrum disease and mandates an extended serologic net.
Next move: Extended myositis blot (Jo-1, PL-7, PL-12, EJ, OJ, MDA5, Ro52), HRCT, PFTs/DLCO, echo for PAH. Crucially, in Delhi NCR, exclude tuberculosis (IGRA ± sputum NAAT) before immunosuppression.
Teaching pearl: Non–Jo-1 synthetase antibodies portend more severe ILD and poorer steroid response — serology is prognostic, not merely diagnostic.
Stage 2: Physical Examination & Initial Evaluation (Timestamp: Admission / Day 1)
Physical Exam: T 38.1°C (febrile), HR 104 bpm, BP 126/78 mmHg, RR 22/min, SpO2 93% room air (improving to 98% on 2L NC).
Physical Findings:
- Hands & Skin: Symmetrical synovitis/swelling of bilateral MCP and PIP joints; hyperkeratotic, scaling, cracked skin over radial aspects of digits bilaterally ("mechanic's hands"); periungual erythema and capillary loop dilation on nailfold capillaroscopy; triphasic Raynaud's change.
- Pulmonary & Cardiac Exam: Fine bibasilar cellophane inspiratory velcro crackles. Muffled heart sounds with a friction rub. Mild proximal lower extremity muscle tenderness/weakness (4+/5 deltoids and iliopsoas).
Hello, Chief Resident here.
Updated Key Findings: The physical examination confirms mild proximal muscle weakness (4+/5), nailfold capillary changes, hypoxia, bibasilar velcro crackles, and a new pericardial friction rub/muffled heart sounds, reinforcing a multi-organ autoimmune myositis spectrum disorder with cardiac involvement.
Updated Differential Diagnoses:
1. Anti-Synthetase Syndrome (ASS) (75%): Probability increases with the full classic pentad now present (ILD, myositis, mechanic’s hands, Raynaud’s, arthritis), plus pericarditis.
2. MDA5+ Dermatomyositis (15%): High concern due to subacute ILD, fever, skin involvement, and proximal weakness; demands urgent rule-out due to rapidly progressive ILD risk.
3. Systemic Sclerosis / Myositis Overlap (7%): Supported by Raynaud’s, capillaroscopy changes, pericarditis, and ILD.
4. Mixed Connective Tissue Disease (MCTD) (3%): Retained given overlap of myositis, polyarthritis, Raynaud's, and serositis (pericarditis).
Prioritized Next Steps:
1. Extended Myositis Autoantibody Blot (Anti-Jo-1, PL-7, PL-12, EJ, OJ, MDA5, Ro-52).
2. Bedside Echocardiogram to assess pericardial effusion, tamponade physiology, and baseline RV pressures.
3. Serum Muscle Enzymes (CPK, Aldolase, Troponin I).
4. High-Resolution CT (HRCT) Chest to evaluate the ILD pattern (NSIP vs. OP).
5. Infectious Pre-screen (TB IGRA, GeneXpert, viral serologies) prior to initiating high-dose immunosuppression.
Hello Attending Consultant here
Top 3 DDx:
1. Anti-synthetase syndrome (non-Jo-1 ARS-predominant)
2. MDA5+ CADM with RP-ILD risk
3. SSc-myositis overlap (sine scleroderma)
Critique of plan: Strong incorporation of new myositis/serositis signs; probabilities appropriately upweighted for ASS. Pericardial rub elevates cardiac urgency beyond listed steps. Capillaroscopy already performed—excellent. Mild weakness does not exclude amyopathic phenotypes.
6 specific refinements:
1. Stat bedside echo + troponin/NT-proBNP now—rub + muffled sounds risk effusion/tamponade or myocarditis.
2. Expand blot to include anti-MDA5/TIF1γ/NXP2; non-Jo-1 + Ro52 drive ILD severity.
3. HRCT same-day; score extent of GGO/consolidation for OP vs NSIP and RP-ILD triage.
4. CK/aldolase/EMG only if rising; avoid delaying Rx for biopsy.
5. Quantiferon + sputum Xpert mandatory (Delhi NCR) pre-steroids/MMF/ritux.
6. Hold empiric high-dose steroids pending echo/serology; low-threshold IVIG if hypoxemia worsens.
7. ILD-rheum-cards MDT within 24 h.
Hello, Expert Clinician here.
Best unifying diagnosis: Anti-synthetase syndrome with the complete pentad — ILD, myositis, mechanic's hands, Raynaud's, arthritis — now complicated by serositis (pericarditis). Non–Jo-1 ARS (PL-7/PL-12) remains favored given ILD-dominant, mild-myositis phenotype.
Top differentials:
- MDA5+ CADM: mechanic's hands, fever, ILD fit; mild weakness and pericarditis less typical, but RP-ILD risk mandates exclusion.
- SSc-myositis overlap: capillaroscopy, Raynaud's, pericarditis fit; mechanic's hands and arthritis favor ASS.
- MCTD: serositis + overlap features fit; requires anti-U1-RNP dominance.
Key pivot: The pericardial friction rub — it transforms this from a lung-joint syndrome into a multi-serosal CTD and introduces an immediate tamponade/myocarditis threat that outranks diagnostic completeness.
Next move: Stat bedside echocardiogram with troponin-I and NT-proBNP to exclude effusion/tamponade and myopericarditis before any immunosuppression; simultaneously send extended myositis blot and TB screening (IGRA + Xpert — non-negotiable in Delhi NCR).
Teaching pearl: Pericarditis in a myositis-spectrum patient is a red flag for overlap disease and cardiac involvement — never attribute chest pressure to ILD alone.
Stage 3: Multi-Modal Laboratory, Serologic & Imaging Diagnostics (Timestamp: Hospital Days 1-3)
Diagnostic Workup:
- Inflammatory & Muscle Enzymes: ESR 82 mm/hr, CRP 64 mg/L, Creatine Kinase (CK) 340 U/L (mild elevation), Aldolase 14.2 U/L.
- Autoimmune Serologies: ANA Positive (1:320, cytoplasmic/speckled pattern), Rheumatoid Factor (RF) negative, Anti-CCP negative, Anti-dsDNA negative, ANCA negative.
- Echocardiogram: Moderate pericardial effusion without cardiac tamponade, preserved LVEF (60%).
- High-Resolution CT (HRCT) Chest: Subpleural ground-glass opacities, bibasilar reticulations, traction bronchiectasis (Non-Specific Interstitial Pneumonia / NSIP pattern), and bilateral pleural effusions (serositis).
Hello, Chief Resident here.
Updated Key Findings: Cytoplasmic ANA (1:320) strongly points to anti-tRNA synthetase antibodies. Mildly elevated CK/aldolase confirms low-grade myositis. HRCT demonstrates an NSIP pattern, while imaging/echo reveals polyserositis (pleural and pericardial effusions without tamponade).
Differential Diagnoses:
1. Anti-Synthetase Syndrome (ASS) (80%): Cytoplasmic ANA pattern, NSIP ILD, mild myositis, mechanic's hands, arthritis, and polyserositis overwhelmingly favor ASS.
2. MDA5+ Dermatomyositis (10%): Remained critical to exclude given subacute ILD and skin changes, though absence of ulceration and presence of overt myositis favor ASS.
3. Systemic Sclerosis / Myositis Overlap (5%): Fits Raynaud's, NSIP, and polyserositis, but cytoplasmic ANA points toward ARS antibodies.
4. Mixed Connective Tissue Disease (MCTD) (5%): Retained due to multi-system serositis, arthritis, and ILD.
Prioritized Management & Diagnostic Steps:
1. Await Extended Myositis Panel (Anti-Jo-1, PL-7, PL-12, EJ, OJ, MDA5, Ro-52) to establish antibody phenotype.
2. Pre-immunosuppression Infectious Screening (TB IGRA/GeneXpert, viral markers).
3. Initiate Pulse IV Methylprednisolone (1g/day for 3 days) bridged to oral steroids with early introduction of Mycophenolate Mofetil or Rituximab.
4. Serial Echocardiograms to monitor pericardial effusion dynamics.
5. Baseline PFTs with DLCO once respiratory status stabilizes.
Hello Attending Consultant here
Top 3 DDx:
1. Anti-synthetase syndrome (non-Jo-1 ARS, NSIP-dominant)
2. MDA5+ CADM (lower probability; NSIP + mild CK atypical for RP-ILD)
3. SSc-myositis overlap / sine scleroderma
Critique of plan: Excellent synthesis of cytoplasmic ANA + NSIP + polyserositis favoring ASS. Probabilities correctly escalated. Premature to lock in pulse steroids + MMF/ritux before full blot and complete TB clearance; mild CK does not mandate immediate high-dose Rx.
6 specific refinements:
1. Expedite extended blot (Jo-1/PL-7/PL-12/EJ/OJ + MDA5/Ro52); cytoplasmic ANA predicts ARS positivity.
2. Confirm negative IGRA/Xpert + viral hepatitis before any steroid pulse.
3. Start methylpred 1 mg/kg (not empiric 1 g pulses) unless hypoxemia worsens; bridge to MMF once serology returns.
4. Serial troponin/NT-proBNP + echo q48h—effusion can progress.
5. PFTs/DLCO + 6MWT pre-discharge for baseline.
6. Add anti-Ro52 titer—synergistic ILD risk marker.
7. MDT (rheum-pulm-cards) review within 24 h; hold ritux pending phenotype.
Hello, Expert Clinician here.
Best unifying diagnosis: Anti-synthetase syndrome, almost certainly non–Jo-1 (PL-7/PL-12) phenotype — cytoplasmic ANA is the signature of anti-tRNA synthetase antibodies, and the NSIP-predominant ILD with mild myositis, mechanic's hands, arthritis, and polyserositis completes the picture.
Top differentials:
- MDA5+ CADM: mechanic's hands and ILD fit, but overt myositis, NSIP (rather than rapidly progressive consolidation), and polyserositis argue against.
- SSc-myositis overlap: Raynaud's, capillaroscopy, NSIP, serositis fit; cytoplasmic ANA and mechanic's hands favor ASS.
- MCTD: polyserositis fits, but requires anti-U1-RNP; cytoplasmic ANA pattern is atypical.
Key pivot: The cytoplasmic ANA staining pattern — it is the serologic fingerprint of aminoacyl-tRNA synthetase antibodies and effectively closes the diagnostic loop before the blot returns.
Next move: Confirm with extended myositis blot (including Ro52 — a prognostic amplifier), complete TB/hepatitis clearance, then initiate corticosteroids (1 mg/kg) with early steroid-sparing agent (MMF or rituximab); serial echoes to track the effusion.
Teaching pearl: A cytoplasmic ANA pattern should always trigger a myositis antibody panel — it reflects cytoplasmic tRNA synthetase antigens, not nuclear ones.
Stage 4: Myositis Panel & Specialized Autoantibody Confirmation (Timestamp: Hospital Days 3-5)
Comprehensive Myositis Specific Autoantibody (MSA) Panel:
- Anti-Jo-1 (Histidyl-tRNA Synthetase) Antibody: Strongly Positive (confirming Anti-Synthetase Syndrome).
- Anti-PL-7, Anti-PL-12, Anti-EJ, Anti-OJ: Negative.
- Anti-Mi-2, Anti-MDA5, Anti-TIF1-gamma: Negative.
- Diagnostic Criteria Fulfillment: Meets Connors and Solomon diagnostic criteria for Anti-Synthetase Syndrome (Anti-Jo-1 positive + Interstitial Lung Disease + Inflammatory Polyarthritis + Mechanic's Hands + Raynaud's + Serositis).
Hello, Chief Resident here.
Updated Key Findings: Serologic confirmation of strongly positive Anti-Jo-1 antibodies, establishing a definitive diagnosis of Anti-Synthetase Syndrome (ASS) fulfilling Connors and Solomon diagnostic criteria (NSIP-ILD, inflammatory polyarthritis, mechanic's hands, Raynaud's, mild myositis, polyserositis).
Differential Diagnoses:
1. Anti-Synthetase Syndrome (Anti-Jo-1 Positive) (95%): Confirmed by pathognomonic serology along with the full classic clinical pentad and polyserositis.
2. Systemic Sclerosis / ASS Overlap (3%): Retained briefly given Raynaud's and capillaroscopy findings, though primary ASS accounts for all manifestations.
3. Other Idiopathic Inflammatory Myopathies (2%): Extremely unlikely following clear MSA panel confirmation.
Prioritized Management Steps:
1. Infectious Screening Clearance: Finalize TB IGRA/GeneXpert and viral hepatitis panels before intensifying immunosuppression.
2. Induction Immunosuppression: Initiate Prednisolone (1 mg/kg/day) bridged with a steroid-sparing agent (Mycophenolate Mofetil or Rituximab given ILD and serositis).
3. PJP Prophylaxis: Start Trimethoprim-Sulfamethoxazole for Pneumocystis jirovecii prophylaxis while on high-dose steroids/immunosuppressants.
4. Cardiac & Respiratory Surveillance: Perform repeat echocardiogram in 1–2 weeks to track pericardial effusion resolution; obtain formal baseline PFTs with DLCO prior to discharge.
5. Multidisciplinary Follow-Up: Establish joint Rheumatology-Pulmonology post-discharge care.
Hello Attending Consultant here
Top 3 DDx:
1. Anti-Jo-1 ASS (confirmed; NSIP + polyserositis phenotype)
2. ASS-SSc overlap (minor residual consideration via capillaroscopy)
3. Secondary IPAF mimic (excluded by serology/criteria)
Critique of plan: Accurate confirmation and criteria fulfillment. Induction choice appropriate but ritux vs MMF sequencing underspecified; cardiac surveillance interval too loose given effusion. Prophylaxis and MDT correctly prioritized.
6 specific refinements:
1. Confirm full TB/hepatitis clearance before any escalation.
2. Start prednisone 1 mg/kg + MMF 2–3 g/day immediately; reserve ritux for steroid-refractory ILD or arthritis.
3. Add PJP + osteoporosis prophylaxis day 1.
4. Echo + troponin/NT-proBNP q72h until effusion regresses; cards co-manage.
5. PFTs/DLCO + 6MWT pre-discharge; HRCT re-score at 3 mo.
6. Screen malignancy (age-appropriate) + Ro52 if not already quantified (ILD amplifier).
7. Rheuma-pulm MDT + patient education on RP-ILD red flags within 48 h.
Hello, Expert Clinician here.
Best unifying diagnosis: Confirmed. Anti-Jo-1–positive anti-synthetase syndrome with the complete pentad — ILD (NSIP), myositis, mechanic's hands, Raynaud's, arthritis — plus polyserositis. Diagnostic closure is appropriate; the task now shifts entirely to management and prognostication.
Top differentials: Effectively resolved. Residual considerations:
- ASS-SSc overlap: capillaroscopy changes warrant periodic scleroderma surveillance but do not alter current management.
- Occult malignancy: age-appropriate screening remains prudent in any new myositis diagnosis.
Key pivot: The anti-Jo-1 result itself — it converts a syndromic diagnosis into a treatable, prognostically defined entity. Jo-1 positivity predicts better treatment response than non–Jo-1 ARS but carries high relapse rates on steroid tapering, mandating early steroid-sparing therapy.
Next move: After confirmed TB/hepatitis clearance, initiate prednisone 1 mg/kg with mycophenolate as first-line steroid-sparing agent (ILD-dominant disease), PJP and bone prophylaxis, serial echoes until effusion resolves, and baseline PFTs/DLCO with 3-month HRCT reassessment.
Teaching pearl: In ASS, the antibody is the disease — Jo-1 status guides prognosis (better myositis response, but ILD relapse on taper is the rule), so never taper steroids without a steroid-sparing anchor.
Stage 5: Final Unifying Diagnosis & Immunosuppressive Management (Timestamp: Follow-up & Discharge)
Final Unifying Diagnosis: Anti-Synthetase Syndrome (Anti-Jo-1 Positive) presenting with the classic clinical pentad: Interstitial Lung Disease (NSIP pattern), Inflammatory Polyarthritis, Mechanic's Hands, Raynaud's Phenomenon, and Serositis (Pericardial and Pleural Effusions).
Treatment Plan:
- Induction: Pulse IV Methylprednisolone 1g daily x 3 days, followed by oral Prednisone 1 mg/kg/day with a structured taper.
- Steroid-Sparing Immunosuppression: Oral Mycophenolate Mofetil (CellCept 1g BID) + Rituximab 1000mg IV induction for severe ILD/serositis.
- Outcome: Rapid resolution of pericardial/pleural effusions, improvement in dyspnea, clearance of mechanic's hands, and stabilization of pulmonary function tests (FVC / DLCO) at 6-month follow-up.
Hello, Chief Resident here.
Updated Key Findings: Definitive Anti-Jo-1 positive Anti-Synthetase Syndrome (ASS) presenting with the full classic pentad (NSIP-ILD, inflammatory polyarthritis, mechanic's hands, Raynaud's, myositis) and polyserositis, achieving near-complete clinical, echocardiographic, and pulmonary stabilization following combination immunosuppression (steroids, MMF, and Rituximab).
Final Differential Diagnoses:
1. Anti-Synthetase Syndrome (Anti-Jo-1 Positive) (98%): Confirmed by pathognomonic autoantibodies, classic clinical criteria, NSIP pattern, and robust treatment response.
2. Systemic Sclerosis / ASS Overlap Spectrum (2%): Minor residual consideration based on nailfold capillaroscopy abnormalities, requiring long-term monitoring.
Long-Term Management & Follow-up Plan:
1. Immunosuppressive Maintenance: Continue Mycophenolate Mofetil (1g BID) with a structured, slow Prednisone taper; evaluate for repeat Rituximab dosing at 6 months based on B-cell repletion and clinical status.
2. Pulmonary Surveillance: Perform PFTs with DLCO every 3–6 months and repeat HRCT chest at 12 months to monitor ILD stability.
3. Cardiovascular Care: Annual echocardiography to monitor for subclinical recurrence of pericardial effusion or secondary pulmonary arterial hypertension.
4. Prophylaxis: Continue Trimethoprim-Sulfamethoxazole for PJP prophylaxis while on moderate-to-high dose immunosuppression; initiate bone protection (bisphosphonates, calcium, vitamin D).
5. Screening: Complete age-appropriate malignancy screening.
Hello Attending Consultant here
Top 3 DDx:
1. Confirmed Anti-Jo-1 ASS (NSIP + polyserositis phenotype)
2. ASS-SSc overlap (capillaroscopy residual)
3. Post-treatment IPAF mimic (excluded)
Critique of plan: Diagnosis locked correctly; outcome excellent. Dual induction (pulse + MMF + RTX) is aggressive yet justified for serositis/ILD, but RTX timing and infection risk underspecified. Long-term surveillance solid; taper protocol and malignancy screen incomplete.
6 specific refinements:
1. Document full pre-RTX TB/hepatitis/PJP clearance and IgG levels.
2. Prefer MMF monotherapy first-line; add RTX only if FVC/DLCO decline or B-cell driven relapse.
3. Structured prednisone taper (10% q2–4 wk) anchored to PFTs; never drop below 5–7.5 mg without steroid-sparing.
4. Serial PFTs/DLCO q3 mo × 1 yr then q6; HRCT only on decline.
5. Echo + NT-proBNP at 6/12 mo for PAH; continue bone/PJP prophylaxis until prednisone <10 mg.
6. Age-appropriate malignancy screen + annual flu/pneumococcal vaccines.
7. Rheuma-pulm MDT + patient RP-ILD action plan at discharge.
Hello, Expert Clinician here.
Best unifying diagnosis: Confirmed and treatment-validated — anti-Jo-1 anti-synthetase syndrome with the full pentad plus polyserositis, demonstrating the expected brisk response to combination immunosuppression. The case is diagnostically closed; the narrative now is relapse prevention.
Top differentials: Resolved. Residual surveillance items:
- ASS-SSc overlap: capillaroscopy abnormalities warrant periodic scleroderma-feature review.
- Relapse on taper: the single greatest threat — Jo-1 ILD characteristically flares during steroid weaning.
Key pivot: The treatment response itself is the final diagnostic confirmation — rapid serositis resolution and PFT stabilization after steroids/MMF/rituximab retrospectively validate the autoimmune etiology and exclude mimics (infection, malignancy, drug-induced ILD).
Next move: Anchor long-term care on a disciplined prednisone taper (never below 5–7.5 mg without steroid-sparing cover), PFTs/DLCO every 3 months for the first year, annual echo for PAH surveillance, sustained PJP/bone prophylaxis, and a written patient action plan for RP-ILD warning signs.
Teaching pearl: In ASS, treatment response is a diagnostic test — but the disease's defining behavior is relapse on taper; the steroid-sparing agent, not the steroid, is the true disease controller.